BIAF bioAffinity Technologies, Inc.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1712762 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-18.5%
TTM net income YoY-4.6%
TTM EPS YoY182.9%
Revenue 3-yr CAGR37.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-246.1%
Net margin-278.9%
FCF margin-235.9%
EBITDA margin-239.5%
Returns
ROE-240.5%
ROA-161.4%
ROIC (approx.)-827.2%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets48.2%
Debt / equity0.00x
Current ratio1.51x
Interest coverage-270.95x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-26.7%
Payout ratio—
Capex / revenue3.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.07M | $1.51M | $1.35M | $1.59M | $1.45M | $1.27M | $1.85M | $2.21M |
| R&D expense | $389,122 | $361,575 | $349,707 | $374,012 | $330,589 | $311,372 | $367,386 | $390,658 |
| SG&A expense | $2.76M | $2.86M | $3.24M | $3.04M | $2.21M | $2.21M | $2.45M | $2.92M |
| Operating income | -$3.51M | -$3.33M | -$3.62M | -$3.14M | -$2.29M | -$2.52M | -$2.63M | -$2.95M |
| Interest expense | $10,713 | $11,688 | $14,722 | $13,069 | $5,358 | $10,460 | $15,485 | $25,045 |
| Pretax income | -$5.28M | -$3.37M | -$3.63M | -$3.13M | -$5.05M | -$4.03M | -$2.65M | -$2.97M |
| Income tax | — | — | — | $3,181 | $3,182 | $28,984 | $8,695 | $0 |
| Net income | -$5.28M | -$3.37M | -$3.63M | -$3.14M | -$5.05M | -$4.06M | -$2.66M | -$2.97M |
| EBITDA | -$3.44M | -$3.27M | -$3.50M | -$3.01M | -$2.18M | -$2.40M | -$2.47M | -$2.79M |
| EPS (basic) | -5.89 | -0.64 | -0.81 | — | -71.05 | -5.07 | -4.80 | — |
| EPS (diluted) | -5.89 | -0.64 | -0.81 | — | -71.05 | -5.07 | -4.80 | — |
| Weighted avg. shares (diluted) | 896,271 | 5.23M | 4.49M | — | 71,090 | 800,637 | 541,841 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.55M | $2.43M | $3.10M | $6.45M | $7.67M | $802,835 | $444,706 | $1.11M |
| Inventory | $108,754 | $82,378 | $77,887 | $53,548 | $35,234 | $43,971 | $38,782 | $27,608 |
| Current assets | $3.83M | $3.87M | $4.34M | $7.57M | $8.61M | $1.67M | $1.86M | $2.70M |
| PP&E, net | $362,359 | $313,708 | $246,849 | $265,593 | $303,122 | $351,368 | $382,409 | $375,385 |
| Goodwill | $1.40M | $1.40M | $1.40M | $1.40M | $1.40M | $1.40M | $1.40M | $1.40M |
| Intangibles | $673,056 | $687,639 | $702,222 | $716,806 | $731,389 | $745,972 | $760,556 | $775,139 |
| Total assets | $7.55M | $7.62M | $7.95M | $10.96M | $11.55M | $4.75M | $5.55M | $6.51M |
| Current liabilities | $2.53M | $2.68M | $3.18M | $2.91M | $2.36M | $2.59M | $3.42M | $3.10M |
| Short-term debt | $160,000 | — | — | — | $260,000 | — | — | — |
| Total liabilities | $3.64M | $3.85M | $4.28M | $3.68M | $2.64M | $6.89M | $4.11M | $3.91M |
| Shareholders' equity | $3.91M | $3.77M | $3.65M | $7.28M | $8.90M | -$2.14M | $1.44M | $2.60M |
| Shares outstanding | 1.17M | 6.78M | 4.50M | 299,826 | 3.47M | 28.46M | 18.26M | 519,158 |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.87M | -$3.20M | -$3.23M | -$2.56M | -$2.48M | -$2.65M | -$1.64M | -$1.68M |
| Capital expenditure | $77,050 | $89,970 | $5,663 | $1 | -$3,646 | $13,427 | $50,786 | $1 |
| Free cash flow | -$3.95M | -$3.29M | -$3.23M | -$2.56M | -$2.48M | -$2.66M | -$1.69M | -$1.68M |
| Investing cash flow | -$77,050 | -$89,970 | -$5,663 | -$1 | $3,646 | -$13,427 | -$50,786 | -$1 |
| Financing cash flow | $4.07M | $2.62M | -$118,513 | $1.34M | $9.34M | $3.02M | $1.03M | $2.03M |
| Depreciation & amortization | $66,842 | $61,556 | $114,518 | $123,659 | $113,360 | $113,229 | $154,588 | $153,632 |
| Stock-based compensation | $138,893 | $784,941 | $14,340 | $66,119 | $67,132 | $211,607 | $326,616 | $234,087 |
Free plan shows the latest 8 periods; Pro shows all 21 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.